Balanced news tone
News Sentiment
IBX sentiment intelligence
Imagion Biosystems Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
21 relevant articles
Price is moving more forcefully than the current news tone suggests.
92/100 classification confidence.
directly relevant articles
high-authority source matches
+9.1% over one week, -25.0% over four weeks, trend inactive, and below fair value.
Is Imagion Biosystems Ltd (ASX: IBX) an ASX MedTech Stock to Watch?
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
92/100 classification
One-week reaction
9.1%
Price confirming higher
Trend fit
Trend inactive
-25.0% over four weeks
Fair value
-89.5%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
4
Neutral
17
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Kalkine
Direct company coverage
Is Imagion Biosystems Ltd (ASX: IBX) an ASX MedTech Stock to Watch?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 03:26
- Source
- Kalkine
Femtech Insider
Direct company coverage
Imagion Biosystems Raises AU$3.75M; Extends Siemens Partnership to Advance Breast Cancer Trial
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 10 Jul 2026 06:38
- Source
- Femtech Insider
Kalkine
Direct company coverage
Imagion Biosystems Completes Placement of 49.3 Million Shares at $0.012, Bringing Total Ordinary Shares on Issue to 539.9 Million
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 07:00
- Source
- Kalkine
Kalkine
Direct company coverage
Imagion Biosystems Issues 49.3 Million Shares at 1.2 Cents Each in Tranche 1 Placement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 05:26
- Source
- Kalkine
Pulse 2.0
Direct company coverage
Imagion Biosystems Secures AU$3.75 Million Capital Raise
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 26 Jun 2026 12:23
- Source
- Pulse 2.0
Investing.com Nigeria
Direct company coverage
Imagion Biosystems raises AU$3.75M for breast cancer trial By Investing.com
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 25 Jun 2026 17:23
- Source
- Investing.com Nigeria
Market source
Direct company coverage
Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- Market source
The Australian
Direct company coverage
StockTake: Imagion Biosystems
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- The Australian
Kalkine
Direct company coverage
Imagion Biosystems Issues 6.2 Million Performance Rights to Directors Under Shareholder-Approved Incentive Scheme
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 05:27
- Source
- Kalkine
Business Wire
Direct company coverage
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Business Wire
The Australian
Direct company coverage
Imagion receives FDA trial clearance
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- The Australian
Stocks Down Under
Direct company coverage
Imagion Biosystems (ASX:IBX) gets FDA green light for HER2 trial, recruitment starts Q3
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Stocks Down Under
Business Wire
Direct company coverage
Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Feb 2026 08:00
- Source
- Business Wire
SMH.com.au
Direct company coverage
ASX Runners of the Week: 333D, Imagion Biosciences, Zenith & Locksley
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Sep 2025 07:00
- Source
- SMH.com.au
Stocks Down Under
Direct company coverage
Imagion Biosystems (ASX:IBX) is getting ready for a Phase 2 study: Interview with Chair Bob Proulx
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Aug 2025 07:00
- Source
- Stocks Down Under
Stocks Down Under
Direct company coverage
Imagion Biosystems (ASX:IBX) gets ready for Phase 2
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Aug 2025 05:41
- Source
- Stocks Down Under
The Motley Fool Australia
Direct company coverage
The Imagion Biosystems (ASX:IBX) share price just exploded by 60%. Here's why
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Mar 2022 07:00
- Source
- The Motley Fool Australia
Kalkine
Direct company coverage
We're Hopeful That Imagion Biosystems (ASX:IBX) Will Use Its Cash Wisely
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 06 Nov 2021 07:00
- Source
- Kalkine
intelligentinvestor.com.au
Direct company coverage
Imagion Biosystems Limited (ASX: IBX) - Share Price
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Feb 2020 21:54
- Source
- intelligentinvestor.com.au
intelligentinvestor.com.au
Direct company coverage
Imagion Biosystems Limited (ASX: IBX) - Announcements
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Oct 2019 09:30
- Source
- intelligentinvestor.com.au
TradingView
Direct company coverage
IBX Stock Price and Chart — ASX:IBX
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jul 2017 14:02
- Source
- TradingView